HRT Financial
VTGN icon

HRT Financial’s VistaGen Therapeutics VTGN Stock Holding History

HRT Financial’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,370
Closed -$14K – 5458
2026
Q1 		$14K Sell
25,370
-12,215
-32% -$7.42K ﹤0.01% 3608
2025
Q4 		$24K Buy
+37,585
New +$136K ﹤0.01% 2967
2022
Q3 		– Sell
-629
Closed -$16K – 3564
2022
Q2 		$16K Sell
629
-8,947
-93% -$316K ﹤0.01% 2632
2022
Q1 		$356K Buy
9,576
+7,641
+395% +$333K ﹤0.01% 2112
2021
Q4 		$113K Buy
+1,935
New +$126K ﹤0.01% 2725
2021
Q2 		– Sell
-5,582
Closed -$356K – 3597
2021
Q1 		$356K Buy
+5,582
New +$373K ﹤0.01% 2012

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

HRT Financial's VTGN Position: Q2 2026 in Review

HRT Financial sold out of VistaGen Therapeutics (VTGN) in Q2 2026, closing a stake of 25,370 shares — an estimated $14K sold.

HRT Financial first reported a position in VTGN in Q1 2021 and held it in 6 quarters. The position peaked at $356K in Q1 2022. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • HRT Financial reported no remaining VistaGen Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 25,370 VistaGen Therapeutics shares in Q2 2026, an estimated $14K.
  • HRT Financial first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 6 quarters.
  • HRT Financial's VistaGen Therapeutics position peaked at $356K in Q1 2022.
  • 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.